New approaches for inhibiting HIV integrase: A journey beyond the active site

Current Opinion in Investigational Drugs

Volumn 10, Issue 2, 2009, Pages 129-136

  Walker, M A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

AIDS; HIV integrase; Lens epithelium derived growth factor; Pyridoxal phosphate

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOPHENONE; D 77; ELVITEGRAVIR; INT 349; INTEGRASE; INTEGRASE INHIBITOR; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P75; PYRIDOXAL 5 PHOSPHATE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; COVALENT BOND; CROSS RESISTANCE; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; NONHUMAN; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS DNA CELL DNA INTERACTION;

BINDING SITES; CATALYTIC DOMAIN; CLINICAL TRIALS, PHASE III AS TOPIC; FORECASTING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; PYRIDOXAL PHOSPHATE;

EID: 62249176335     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Gonzalez Paz O, Hazuda DJ, Jones P et al: Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem (2008) 51(18):5843-5855.
2. Havlir DV: HIV integrase inhibitors - Out of the pipeline and into the clinic. N Engl J Med (2008) 359(4):416-418.
3. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C et al: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 359(4):339-354.
4. DeJesus E, Berger D, Markowitz M, Cohen C, Hawkins T, Ruane P, Elion R, Farthing C, Cheng A, Kearney BP: The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients. Conference on Retroviruses and Opportunistic Infections (2006) 13:Abs 160LB.
5. Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA: Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS (2007) 21(17):2315-2321.
6. Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N: HIV-1 integrase inhibitors: 2005-2006 update. Med Res Rev (2008) 28(1):118- 154.
7. Egbertson MS: HIV integrase inhibitors: From diketoacids to heterocyclic templates: A history of HIV integrase medicinal chemistry at Merck West Point and Merck Rome (IRBM). Curr Top Med Chem (2007) 7(13):1251-1272.
8. Nair V, Chi G: HIV integrase inhibitors as therapeutic agents in AIDS. Rev Med Virol (2007) 17(4):277-295.
9. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M et al: Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2008) 82(2):764-774.
10. Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C et al: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother (2008) 52(4):1351-1358.
11. Goethals O, Clayton R, Van Ginderen M, Vereycken I, Wagemans E, Geluykens P, Dockx K, Strijbos R, Smits V, Vos A, Meersseman G et al: Resistance mutations in HIV-1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 82(21):10366-10374.
12. Wiscount CM, Williams PD, Tran LO, Embrey MW, Fisher TE, Sherman V, Homnick CF, Donnette Staas D, Lyle TA, Wai JS, Vacca JP et al: 10-Hydroxy-7,8-dihydropyrazino[1′,2′:1,5] pyrrolo[2,3- d]pyridazine-1,9(2H,6H)-diones: Potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants. Bioorg Med Chem Lett (2008) 18(16):4581-4583.
13. Al-Mawsawi LQ, Neamati N: Blocking interactions between HIV-1 integrase and cellular cofactors: An emerging antiretroviral strategy. Trends Pharmacol Sci (2007) 28(10):526-535.
14. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z: Cellular co-factors of HIV-1 integration. Trends Biochem Sci (2006) 31(2):98-105.
15. Ge H, Si Y, Roeder RG: Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. EMBO J (1998) 17(22):6723-6729.
16. Shinohara T, Singh DP, Fatma N: LEDGF, a survival factor, activates stress-related genes. Prog Retin Eye Res (2002) 21(3):341-358.
17. Nishizawa Y, Usukura J, Singh DP, Chylack LT Jr, Shinohara T: Spatial and temporal dynamics of two alternatively spliced regulatory factors, lens epithelium-derived growth factor (LEDGF/p75) and p52, in the nucleus. Cell Tissue Res (2001) 305(1):107-114.
18. McKee CJ, Kessl JJ, Shkriabai N, Dar MJ, Engelman A, Kvaratskhelia M: Dynamic modulation of HIV-1 integrase structure and function by cellular LEDGF protein. J Biol Chem (2008) 283(46):31802-31812.
19. Lataillade M, Chiarella J, Kozal MJ: Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther (2007) 12(4):563-570. • The LEDGF-binding domain located on IN is a conserved region.
20. Engelman A, Cherepanov P: The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog (2008) 4(3):e1000046.
21. Poeschla EM: Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci (2008) 65(9):1403-1424.
22. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, Debyser Z: HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2003) 278(1):372-381.
23. Turlure F, Devroe E, Silver PA, Engelman A: Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci (2004) 9(Suppl):3187-3208.
24. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, Tempe D, Vandekerckhove L, Moisant F, Ben-Slama L, Witvrouw M, Christ F et al: Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem (2005) 280(27):25517-25523.
25. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM: An essential role for LEDGF/p75 in HIV integration. Science (2006) 314(5798):461-464.
26. Shun MC, Raghavendra NK Vandegraaff N, Daigle JE, Hughes S, Kellam P, Cherepanov P, Engelman A: LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev (2007) 21(14):1767-1778.
27. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, Engelborghs Y: LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem (2003) 278(35):33528-33539.
28. Llano M, Vanegas M, Fregoso O, Saenz D, Chung S, Peretz M, Poeschla EM: LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol (2004) 78(17):9524-9537.
29. Cherepanov P, Devroe E, Silver PA, Engelman A: Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem (2004) 279(47):48883-48892.
30. Cherepanov P: LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res (2007) 35(1):113-124.
31. Botbol Y, Raghavendra NK, Rahman S, Engelman A, Lavigne M: Chromatinized templates reveal the requirement for the LEDGF/p75 PWWP domain during HIV-1 integration in vitro. Nucleic Acids Res (2008) 36(4):1237-1246. • It was demonstrated that chromatinized-DNA provides a better target substrate for LEDGF-dependent HIV integration compared with isolated naked DNA.
32. Pruss D, Reeves R, Bushman FD, Wolffe AP: The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J Biol Chem (1994) 269(40):25031-25041.
33. Al-Mawsawi LQ, Hombrouck A, Dayam R, Debyser Z, Neamati N: Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity. Virology (2008) 377(2):355-363.
34. Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A: Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium. Proc Nat Acad Sci USA (2007) 104(20):8316-8321. • A mechanism for dominate-negative inhibition of IN by LEDGF fragments is presented.
35. Cherepanov P, Sun ZYJ, Rahman S, Maertens G, Wagner G, Engelman A: Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol (2005) 12(6):526-532.
36. Cherepanov P, Ambrosio ALB, Rahman S, Ellenberger T, Engelman A: Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Nat Acad Sci USA (2005) 102(48):17308-17313. • The X-ray structure determination of the IN-binding domain of LEDGF in complex with the catalytic core of IN is described.
37. De Rijck J, Vandekerckhove L, Gijsbers R, Hombrouck A, Hendrix J, Vercammen J, Engelborghs Y, Christ F, Debyser Z: Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol (2006) 80(23):11498-11509. • This paper reports that inhibition of LEDGF-dependent integration reduces HIV infectivity.
38. Hombrouck A, De Rijck J, Hendrix J, Vandekerckhove L, Voet A, De Maeyer M, Witvrouw M, Engelborghs Y, Christ F, Gijsbers R, Debyser Z: Virus evolution reveals an exclusive role for LEDGF/p75 in chromosomal tethering of HIV. PLoS Pathog (2007) 3(3):e47.
39. Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N: Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: Insight into integrase - DNA complex formation and catalysis. FEBS Lett (2008) 582(10):1425-1430.
40. Hou Y, McGuinness DE, Prongay AJ, Feld B, Ingravallo P, Ogert RA., Lunn CA, Howe JA: Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J Biomol Screening (2008) 13(5):406-414.
41. Du L, Zhao Y, Chen J, Yang L, Zheng Y, Tang Y, Shen X, Jiang H: D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun (2008) 375(1):139-144.
42. Al-Mawsawi LQ, Fikkert V, Dayam R, Witvrouw M, Burke TR Jr, Borchers CH, Neamati N: Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. Proc Nat Acad Sci USA (2006) 103(26):10080-10085.
43. Molteni V, Greenwald J, Rhodes D, Hwang Y, Kwiatkowski W, Bushman FD, Siegel JS, Choe S: Identification of a small-molecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr D Biol Crystallogr (2001) 57:536-544.
44. Shkriabai N, Patil SS, Hess S, Budihas SR, Craigie R, Burke TR Jr, Le Grice SF, Kvaratskhelia M: Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. Proc Natl Acad Sci (2004) 101(18):6894-6899.
45. Esposito D, Craigie R: Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical regions for protein-DNA interaction. EMBO J (1998) 17(19):5832-5843. • The C-terminal domain of HIV IN was found to bind to viral DNA.
46. Heuer TS, Brown PO: Photo-crosslinking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex. Biochemistry (1998) 37(19):6667-6678. • The C-terminal domain of HIV IN was found to bind to viral DNA.
47. Eijkelenboom APAM, Lutzke RAP, Boelens R, Plasterk RHA, Kaptein R, Hard K: The DNA-binding domain of HIV-1 integrase has an SH3-like fold. Nat Struct Biol (1995) 2(9):807-810. • The structure of the C-terminal domain of HIV IN was determined by NMR analysis.
48. Lutzke RA, Vink C, Plasterk RHA: Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res (1994) 22(20):4125-4131.
49. Chen JC, Krucinski J, Miercke LJ, Finer-Moore JS, Tang AH, Leavitt AD, Stroud RM: Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc Natl Acad Sci USA (2000) 97(15):8233-8238.
50. 246 is involved in viral DNA binding.
51. Williams KL, Zhang Y, Shkriabai N, Karki RG, Nicklaus MC, Kotrikadze N, Hess S, Le Grice SF, Craigie R, Pathak VK, Kvaratskhelia M: Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5′-phosphate complex reveals a new binding site for a nucleotide inhibitor. J Biol Chem (2005) 280(9):7949-7955.
52. Guo L, Heinzinger NK, Stevenson M, Schopfer LM, Salhany JM: Inhibition of gp120-CD4 interaction and human immunodeficiency virus type 1 infection in vitro by pyridoxal 5′-phosphate. Antimicrob Agents Chemother (1994) 38(10):2483-2487. • HIV entry was inhibited by PLP in vitro.
53. Salhany JM, Schopfer LM: Pyridoxal 5′-phosphate binds specifically to soluble CD4 protein, the HIV-1 receptor. Implications for AIDS therapy. J Biol Chem (1993) 268(11):7643-7645.
54. Mazumder A, Neamati N, Sommadossi JP, Gosselin G, Schinazi RF, Imbach JL, Pommier Y: Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol Pharmacol (1996) 49(9):621-628 • HIV entry was inhibited by PLP in vitro.
55. Mathé C, Nair V: Potential inhibitors of HIV integrase. Nucleosides Nucleotides (1999) 18(4-5):681-682. • HIV IN was inhibited by PLP in vitro.
56. Wu JJ, Milot G, Gouveia K, Dandache S, Xiao Y, Ge M, Oudanonh T, Bouchard JE, Stranix BR: Pyrazolopyridine compounds as novel HIV-1 integrase inhibitors. Interscience Conference on Antimicrobial Agents and Chemotherapy (2007) 47:Abs H-1045.
57. Wu JJ, Milot G, Dandache S, Gouveia K, Xiao Y, Yelle J, Sevigny G, Dubois A, Tian B, Perron V, Herbart D, Stranix BR: Novel small molecule inhibitors of HIV-1 integrase. International HIV Drug Resistance Workshop (2007) 16:Abs 6.
58. Ambrilia BioPharma Inc: Ambrilia prioritizes its divestment strategy and takes cost-cutting actions to extend cash. Press release (2008): 29 September.